Day: February 22, 2021

SANTA MONICA, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the fourth quarter and year ended December 31, 2020, after the financial markets close on Thursday March 4, 2021.  The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday March 4, 2021. To access the call, please dial 877-407-0792 in the U.S. or 201-689-8263 outside the U.S. and provide the conference ID number: 13715395. To access the live webcast, please go to the investors section of Opiant’s website at http://ir.opiant.com/. Following the live webcast, an archived version of the call will be available on the website.About Opiant Pharmaceuticals,...

ALACHUA, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020.Fourth Quarter 2020 Financial Results and Business HighlightsNet revenue was $32.5 million during the quarter, a 15% increase compared to fourth quarter 2019 revenue of $28.2 million.Gross margin was 83.2% for the quarter, compared to 82.7% in the fourth quarter of 2019.Net loss for the quarter was $6.0 million, or $0.15 per share, compared to a net loss of $7.0 million, or $0.18 per share, in the fourth quarter of 2019.Adjusted net loss was $3.3 million for the quarter, or $0.08 per share, compared with adjusted net loss of $4.0 million,...

CALGARY, Alberta, Feb. 22, 2021 (GLOBE NEWSWIRE) — Gibson Energy Inc. announced today that its Board of Directors has approved a quarterly dividend of $0.35 per common share, an increase of $0.01 per common share, which will be payable on April 16, 2021, to shareholders of record at the close of business on March 31, 2021. This dividend is designated as an eligible dividend for Canadian income tax purposes. For non-resident shareholders, Gibson’s dividends are subject to Canadian withholding tax.“Despite the challenging environment over the past year, we grew our long-term, stable cash flows from our Infrastructure segment by nearly 20 percent on a year over year comparable basis,” said Steve Spaulding, President and Chief Executive Officer. “Our Infrastructure business also demonstrated its resilience through 2020, which gives...

Pre-Clinical Data Support the Potential Benefit of XEN1101 to Treat Depression and AnhedoniaXEN1101, in Combination with Other Anti-Seizure Medications, Provides Robust Efficacy in Animal ModelsTopline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Third Quarter of 2021BURNABY, British Columbia, Feb. 22, 2021 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced that new pre-clinical data and a clinical overview of its XEN1101 program will be presented at ASENT 2021, the virtual annual meeting of the American Society for Experimental Neurotherapeutics. XEN1101 is a differentiated Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders. The X-TOLE Phase 2b clinical...

All financial figures are in Canadian dollars unless otherwise notedCALGARY, Alberta, Feb. 22, 2021 (GLOBE NEWSWIRE) — Gibson Energy Inc. announced today its financial and operating results for the three months and fiscal year ended December 31, 2020.“Gibson proved very resilient through a challenging year for our industry, a result of our strategic focus on long-term, stable Infrastructure cash flows, maintaining a strong balance sheet and not relying on variable businesses to fund our dividend nor capital program,” said Steve Spaulding, President and Chief Executive Officer. “Despite the challenges of COVID-19, we continued to grow our Infrastructure cash flows, including placing 1.5 million barrels of tankage at our Hardisty Terminal into service near the end of the year and advancing the DRU towards a mid-2021 in-service date....

–Dermatological indication characterized by chronic, intensely itchy nodules; mast cell activation believed to play an important role in amplifying chronic itch and neuroinflammation––Potential to expand future CDX-0159 development beyond chronic urticarias to chronic pruritic diseases and other significant indications driven by itch and neuroinflammation–HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will expand clinical development of CDX-0159 into prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin. Mast cells through their interactions with sensory neurons and other immune cells are believed to play an important role in amplifying chronic itch and...

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at the upcoming 10th Annual SVB Leerink Healthcare Conference on Thursday, February 25, 2021, at 5:00 p.m. EST.The live webcast can be accessed under “Events & Presentations” in the Investors and Media section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for...

REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it will host a conference call and webcast on Monday, March 1, 2021 at 1:30 pm PT/4:30 pm ET to highlight significant progress in the development plans for ADVM-022 in wet AMD, recent business progress, and report fourth quarter 2020 financial results.Key Opinion Leader, Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this call.The live webcast will be accessible under Events and Presentations in the Investors section of the company’s website. To participate in the conference call, dial 1-855-327-6837 (domestic)...